These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 18759214)

  • 41. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
    Chan WM; Lai TY; Liu DT; Lam DS
    Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum.
    Finger RP; Charbel Issa P; Ladewig M; Holz FG; Scholl HP
    Br J Ophthalmol; 2008 Apr; 92(4):483-7. PubMed ID: 18369065
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM; Lai TY; Liu DT; Lam DS
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib].
    Maier M; Feucht N; Huebner M; Lohmann C
    Klin Monbl Augenheilkd; 2008 Jun; 225(6):582-7. PubMed ID: 18516780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD.
    Modarres M; Naseripour M; Falavarjani KG; Nikeghbali A; Hashemi M; Parvaresh MM
    Retina; 2009 Mar; 29(3):319-24. PubMed ID: 19287288
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Arias L; Caminal JM; Casas L; Masuet C; Badia MB; Rubio M; Pujol O; Arruga J
    Br J Ophthalmol; 2008 Dec; 92(12):1636-41. PubMed ID: 18782803
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
    Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
    Retina; 2006; 26(9):994-8. PubMed ID: 17151485
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravitreal bevacizumab for subfoveal choroidal neovascularization associated with pattern dystrophy.
    Parodi MB; Iacono P; Cascavilla M; Zucchiatti I; Kontadakis DS; Bandello F
    Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4358-61. PubMed ID: 20375343
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
    Gupta B; Adewoyin T; Patel SK; Sivaprasad S
    Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
    Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
    Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
    [TBL] [Abstract][Full Text] [Related]  

  • 51. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration.
    Goverdhan SV; Lochhead J
    Br J Ophthalmol; 2008 Feb; 92(2):210-2. PubMed ID: 17965104
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.
    Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A
    Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.
    Michels S; Rosenfeld PJ; Puliafito CA; Marcus EN; Venkatraman AS
    Ophthalmology; 2005 Jun; 112(6):1035-47. PubMed ID: 15936441
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects on choroidal neovascularization after anti-VEGF Upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography.
    Framme C; Panagakis G; Birngruber R
    Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1671-6. PubMed ID: 19875667
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intravitreal bevacizumab (Avastin) in treatment of neovascular age-related macular degeneration.
    Lazić R; Gabrić N; Dekaris I; Sarić B; Gavrić M
    Coll Antropol; 2007 Jan; 31 Suppl 1():77-81. PubMed ID: 17469757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
    Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
    Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions.
    Lux A; Llacer H; Heussen FM; Joussen AM
    Br J Ophthalmol; 2007 Oct; 91(10):1318-22. PubMed ID: 17537784
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The treatment of choroidal neovascularisation with intravitreal injections of bevacizumab (Avastin).
    Valmaggia C; Niederberger H; Lang C; Kloos P; Haueter I
    Klin Monbl Augenheilkd; 2008 May; 225(5):380-4. PubMed ID: 18454377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.